-
公开(公告)号：US07687665B2
公开(公告)日：2010-03-30
申请号：US11159865
申请日：2005-06-23
申请人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
发明人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
IPC分类号： C07C233/05 , A61K31/165
CPC分类号： C07C233/11 , C07C233/13 , C07C233/19 , C07C233/22 , C07C233/23 , C07C235/22 , C07C323/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/28 , C07C2602/42 , C07D209/14 , C07D209/16 , C07D307/22 , C07D319/20
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US20100137401A1
公开(公告)日：2010-06-03
申请号：US12698261
申请日：2010-02-02
申请人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
发明人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
IPC分类号： A61K31/404 , C07C233/07 , A61K31/165 , C12N9/99 , C07D307/22 , A61K31/341 , C07D209/18 , C07D319/16 , A61K31/357 , C07C233/06 , C07C233/05 , A61P3/10 , A61P3/04 , A61P3/06 , A61P9/00 , A61P9/10
CPC分类号： C07C233/11 , C07C233/13 , C07C233/19 , C07C233/22 , C07C233/23 , C07C235/22 , C07C323/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/28 , C07C2602/42 , C07D209/14 , C07D209/16 , C07D307/22 , C07D319/20
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US20060009471A1
公开(公告)日：2006-01-12
申请号：US11159724
申请日：2005-06-23
申请人： Wenqing Yao , Meizhong Xu , Colin Zhang , Konstantinos Agrios , Brian Metcalf , Jincong Zhuo
发明人： Wenqing Yao , Meizhong Xu , Colin Zhang , Konstantinos Agrios , Brian Metcalf , Jincong Zhuo
IPC分类号： A61K31/495 , A61K31/4747 , A61K31/407 , C07D471/10 , C07D491/10
CPC分类号： C07D207/08 , C07D207/06 , C07D209/54 , C07D211/16 , C07D211/22 , C07D211/52 , C07D217/06 , C07D217/16 , C07D221/20 , C07D241/04 , C07D295/108 , C07D295/185 , C07D401/04 , C07D491/04 , C07D491/10 , C07D495/04
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
-
公开(公告)号：US20120122858A1
公开(公告)日：2012-05-17
申请号：US13355219
申请日：2012-01-20
申请人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
发明人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
IPC分类号： A61K31/5355 , A61K31/438 , A61K31/496 , A61K31/506 , A61K31/4725 , A61K31/4709 , A61K31/497 , A61K31/52 , A61K31/517 , C07D487/04 , A61K31/519 , A61P3/04 , A61P3/10 , A61P3/08 , A61P9/12 , A61P3/06 , A61P25/00 , A61P25/24 , A61P25/28 , A61P27/06 , A61P9/00 , A61P19/10 , A61P29/00 , A61P13/12 , A61P9/04 , A61P9/10 , A61P7/02 , A61P3/00 , C07D471/10
CPC分类号： C07D471/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US20080167287A1
公开(公告)日：2008-07-10
申请号：US11942130
申请日：2007-11-19
申请人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
发明人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
IPC分类号： A61K31/397 , C07D253/065 , A61K31/53 , A61K31/496 , C12N5/00 , A61P11/00 , A61P29/00 , A61P9/00 , A61P37/00 , A61P1/16 , A61P35/00 , C12N9/99 , C07D239/70 , A61K31/519
CPC分类号： C07D487/04 , A61K31/4709 , A61K31/53 , C07D403/06
摘要： The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及咪唑并[1,2-b] [1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是诸如c-Met的激酶抑制剂， 可用于治疗与激酶途径失调相关的癌症和其它疾病。
-
公开(公告)号：US20070179142A1
公开(公告)日：2007-08-02
申请号：US11784450
申请日：2007-04-06
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/5375 , A61K31/496 , A61K31/495 , A61K31/445 , A61K31/401
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
-
公开(公告)号：US20130324515A1
公开(公告)日：2013-12-05
申请号：US13895799
申请日：2013-05-16
申请人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Din-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
发明人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Din-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
IPC分类号： C07D487/04
CPC分类号： C07D487/04 , A61K31/4709 , A61K31/53 , C07D403/06
摘要： The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及咪唑并[1,2-b] [1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是诸如c-Met的激酶抑制剂， 可用于治疗与激酶途径失调相关的癌症和其它疾病。
-
公开(公告)号：US08563570B2
公开(公告)日：2013-10-22
申请号：US13355219
申请日：2012-01-20
申请人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
发明人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
IPC分类号： C07D471/10 , A61K31/4439
CPC分类号： C07D471/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11-β羟基类固醇脱氢酶抑制剂，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与1-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
公开(公告)号：US07767675B2
公开(公告)日：2010-08-03
申请号：US11942130
申请日：2007-11-19
申请人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , Brian Metcalf , Wenqing Yao
发明人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , Brian Metcalf , Wenqing Yao
IPC分类号： C07D487/04 , C07D403/04 , C07D403/14 , A61K31/53 , A61K31/5377 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4709 , A61K31/53 , C07D403/06
摘要： The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及咪唑并[1,2-b] [1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是诸如c-Met的激酶抑制剂， 可用于治疗与激酶途径失调相关的癌症和其它疾病。
-
公开(公告)号：US20050288338A1
公开(公告)日：2005-12-29
申请号：US11159862
申请日：2005-06-23
申请人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He , Brian Metcalf
发明人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He , Brian Metcalf
IPC分类号： A61K31/165 , A61K31/44 , A61K31/445 , C07C233/58 , C07C233/60 , C07C233/63 , C07C235/40 , C07C317/44 , C07C323/61 , C07D207/14 , C07D209/14 , C07D211/58 , C07D213/30 , C07D213/38 , C07D213/81 , C07D307/22 , C07D307/38 , C07D309/14 , C07D319/20
CPC分类号： C07C233/58 , C07C233/59 , C07C233/60 , C07C233/63 , C07C235/40 , C07C317/44 , C07C323/61 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/02 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07D207/14 , C07D209/14 , C07D211/58 , C07D211/96 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/81 , C07D295/205 , C07D307/22 , C07D307/33 , C07D307/38 , C07D309/14 , C07D319/20
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11-β羟基类固醇脱氢酶抑制剂，盐皮质激素受体MR的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与1-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.04 秒)
